Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401995 · ClinicalTrials.gov registry record · Phase 2
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
A Phase 2 study, sponsored by Diwakar Davar.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04401995 is a Phase 2 study that has completed, run by Diwakar Davar. The registered enrollment target is 9 participants.
The verdict
NCT04401995, a Phase 2 study, has completed, sponsored by Diwakar Davar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas. The main goal of the PET/CT scan with 18F\]F-AraG is to evaluate how \[18F\]F-AraG uptake changes before and after administration of either nivolumab or nivolumab/CMP-001 combination.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Vidutolimod (CMP-001)
- OTHER [18F]F-AraG PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2024-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401995
The ClinicalTrials.gov registry entry for NCT04401995 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04401995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04401995 about?
NCT04401995 is a clinical study titled "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab". The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas. The main goal of the PET/CT scan with 18F\]F-AraG is to evaluate how \[18F\]F-AraG ...
What is the current status of trial NCT04401995?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-02. Estimated completion is 2024-08-16.
What interventions are being tested in trial NCT04401995?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Vidutolimod (CMP-001) (DRUG), [18F]F-AraG PET/CT (OTHER).
Who is sponsoring clinical trial NCT04401995?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.